You are here: Industry Insights > Market News > Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

firstwordpharmaJuly 13, 2021

Tag: Covaxin , COVID-19 vaccine , WHO

Favorites

Bharat Biotech on Monday said it has submitted all documents required for the emergency use listing of its COVID-19 vaccine Covaxin to the World Health Organization (WHO), as reported by The Economic Times.

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

Last week, WHO chief scientist Soumya Swaminathan said the agency is likely to take a decision on Covaxin’s emergency use listing within four to six weeks.

"All documents required for Emergency Use Listing (EUL) of Covaxin have been submitted to WHO as of 9th July. The review process has now commenced with the expectation that we will receive EUL from WHO at the earliest," tweeted Bharat chairman Krishna Ella.

Previous:Pregnant women to receive Moderna COVID-19 vaccine in clinical trial

Next:Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Rhodiola Rosea Extract Root Wholesale 3% Best Price Powder Organic Rhodioloside Salidroside

Wholesale Price Puhuang Extract

Organic Lion's Mane Extract 30% Seeds Colony Whole Dried Hericium Mushroom Polysaccharides

Wholesale Western Medicine GMP Pharmaceutical Drug Beclomethasone Aerosol

Wholesale Pure Natural Organic Black Pepper Extract Piperine 50% 99% CAS 94-62-2 Piperine

Manufacturer Wholesale Price Natural Organic Supply Food Grade Phytronadione Vitamin K1

Wholesale Price Pea Protein Peptide 100% Pure Powder Private Label

Wholesale Free Sample CAS 9005-65-6 Delbrueckii Subsp.Bulgaricus Lactobacillus Bulgaricus Powder

Wholesale Price Magnesium Glycine Sofegel

Wholesale Price PMS Gummies

Documents for Covaxin emergency use listing submitted to WHO; expect approval at earliest: Bharat Biotech

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>